Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 26, 2009Expert Opinion on Therapeutic Targets

HDACs are identified as attractive therapeutic targets for heart failure, pending in vivo proof-of-concept testing with novel small molecule regulators.

View Full Paper
Ask AI
Bookmark
Share

Population

Heart failure and pathological cardiac remodeling

Design

Review

Authors

EBErik W. BushTMTimothy A. McKinsey

Discussion

Loading...

Member takes

Overview

HDACs merit preclinical pursuit as heart failure targets; leaves open clinical translation pending in vivo validation.

Structured PICO

P
Population
Heart failure and pathological cardiac remodeling
I
Intervention
Histone deacetylase (HDAC) targeted therapies

HDACs are promising therapeutic targets for heart failure, but require further in vivo proof-of-concept testing.

Cite This Study

Bush et al. (2009) studied this question.

synapsesocial.com/papers/6a7d1687f71d7d96a037cab6https://doi.org/10.1517/14728220902939161
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Suppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy2006 · 377 citations
  2. 2HDACs and Their Inhibitors on Post-Translational Modifications: The Regulation of Cardiovascular Disease2025 · 12 citations
  3. 3Histone Deacetylase 7 protects against pathologic cardiac hypertrophy2026 · 1 citations
  4. 4Unlocking cardiac health: exploring the role of class I HDACs in cardiovascular diseases2025
  5. 5Histone deacetylase 4: A therapeutic target for cardiovascular diseases (Review)2025 · 2 citations